Teva launches generic blood pressure treatments

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced Monday that it has commenced commercial launch of both Irbesartan and Irbesartan-Hydrochlorothiazide Tablets, its generic versions of Sanofi Aventis’s high blood pressure treatments, Avapro and Avalide Tablets.
Teva reports that the brand products had annual sales of approximately $464 million and $124 million, respectively in the US, according to IMS sales data.
As the first company to file Abbreviated New Drug Applications (ANDA) containing paragraph IV certifications for both of these products, Teva has been awarded a 180-day period of marketing exclusivity.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy